



















766Expression of neuropeptides and cytokines
in a rabbit model of diabetic neuroischemic
wound healing
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Objective: The present study is designed to understand the contribution of peripheral vascular disease and peripheral
neuropathy to the wound-healing impairment associated with diabetes. Using a rabbit model of diabetic neuroischemic
wound healing, we investigated rate of healing, leukocyte inﬁltration, and expression of cytokines, interleukin-8 and
interleukin-6, and neuropeptides, substance P, and neuropeptide Y.
Methods:Diabetes was induced inNewZealandWhite rabbits by administering alloxanwhile control rabbits received saline.
Ten days later, animals in both groups underwent surgery. One ear served as a sham, and the other was made ischemic
(ligation of centralDrostral arteries) or neuroischemic (ischemiaD resection of centralDrostral nerves). Four 6-mm punch
biopsy wounds were created in both ears and wound healing was followed for 10 days using computerized planimetry.
Results:Nondiabetic sham and ischemic wounds healed signiﬁcantly more rapidly than diabetic sham and ischemic wounds.
Healing was slowest in neuroischemic wounds, irrespective of diabetic status. A highM1/M2macrophage ratio and a high
proinﬂammatory cytokine expression, both indicators of chronic proinﬂammatory state, and low neuropeptide expression
were seen in preinjury diabetic skin. Postinjury, in diabetic wounds, the M1/M2 ratio remained high, the reactive increase
in cytokine expression was low, and neuropeptide expression was further decreased in neuroischemic wounds.
Conclusions: This rabbit model illustrates how a combination of a high M1/M2 ratio, a failure to mount postinjury
cytokine response as well as a diminished neuropeptide expression, contribute to wound-healing impairment in diabetes.
The addition of neuropathy to ischemia leads to equivalently severe impaired wound-healing irrespective of diabetes
status, suggesting that in the presence of ischemia, loss of neuropeptide function contributes to the impaired healing
associated with diabetes. (J Vasc Surg 2013;58:766-75.)
Clinical Relevance: Although, diabetic foot ulceration is a major clinical problem and the most common cause for hospital
admissions in diabetic patients, there is limited basic and translational research. One of the main reasons is the lack of
appropriate animal models that control for factors related to the major complications of diabetes, namely, neuropathy and
ischemia. The aim of this study was to use a clinically relevant animal model of neuroischemic wound healing that is
representative of human diabetic foot ulceration and to examine the contribution of neuropeptides and inﬂammation.
These data, showing a link between neuropeptide and cytokine function, diabetes, and neuroischemia, provide both
a basis and a model for studies of wound-healing therapies.One of the most common complications of both type I mortality.1 The cause of impaired wound-healing in dia-
and type II diabetes is the development of chronic non-
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://dx.doi.org/10.1016/j.jvs.2012.11.095betes is multifactorial and includes vascular, neurologic,
and inﬂammatory alterations.2 Impaired diabetic wound
healing is increased in skin areas that are affected by periph-
eral neuropathy, and there is growing evidence that
cutaneous peripheral nerves regulate immune and cytokine
response via mediators such as neuropeptides substance P
(SP) and neuropeptide Y (NPY).3,4 Our group has shown
that these neuropeptides not only control cytokine release
from leukocytes but also affect endothelial cell function.5 A
recent clinical study by our group also shows that increased
inﬂammation and aberrant growth factor expression in the
skin are associated with failure to heal diabetic foot ulcers.6
In vivo investigation of diabetes-related impaired
wound healing is most commonly performed in rodent
models because of their economic feasibility, shorter repro-
duction times, and accessibility to genetically engineered
mice models. However, skin healing in rodents is largely
mediated through contraction, whereas in humans, it
occurs through re-epithelialization. Rabbit ear skin is
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a major heat-exchange surface and are controlled by the
autonomic nervous system for thermoregulation.7-9 Both
SP- and NPY-releasing nerves innervate the rabbit ear
and are involved in controlling the vascular tone, more
speciﬁcally for thermoregulation.10 A previous study from
our lab that employed the rabbit ear wound healing model
showed that diabetes affects the focused inﬂammatory
cytokine response to injury and dysregulates neuropeptide
gene expression, but this study did not assess the role of
vascular ischemia and neuropathy, two of the major
contributing factors of diabetes-associated complications.11
Our hypothesis is that in addition to vascular ischemia,
neuropeptide dysregulation resulting in the alteration of
inﬂammatory response will impair wound healing in diabetic
rabbits. To test our hypothesis, we used a rabbit neuroische-
mic model of ear wound healing similar to the model used
by Chien et al12 in which, the intact cartilage stents the
wound open and hence most of the healing occurs through
re-epithelialization.13 Our study is the ﬁrst to use this model
to provide a comprehensive analysis of the combined effects
of diabetes, ischemia, and denervation on wound healing.
Changes in immune cell inﬁltration, gene and protein
expression of inﬂammatory cytokines, neuropeptides, their
receptors, and associated proteins were evaluated. Speciﬁ-
cally, the inﬁltration of HLA-DRþ M1 macrophages,
responsible for the development of chronic wounds,
CD206þ M2 macrophages, involved in tissue repair,
CD177þ neutrophils and CD3þ T cells were evaluated.
The expression of cytokines, interleukin (IL)-6, IL-8 and,
IL-8 receptor, C-X-C chemokine receptor 1 (CXCR1), all
of which are pivotal for wound healing were assessed. We
also analyzed the expression of SP and its predominant
receptor neurokinin 1 receptor (NK1R), NPY, and its
proangiogenic receptors NPY2R and NPY5R, the enzyme
neprilysin (NEP) that metabolizes SP and the enzyme
nipeptidyl peptidase IV (DPPIV) that cleaves the 36 amino
acid NPY to the angiogenic form, NPY3-36.4
METHODS
Rabbits. New Zealand White rabbits (3.0-3.2 kg;
Millbrook Farms, Amherst, Mass) received 75 mg/kg,
i.v. alloxan monohydrate (diabetic group) or saline (nondi-
abetic group) on day 0. After 48 hours, rabbits that did not
become diabetic with the ﬁrst alloxan injection received
another 75 mg/kg alloxan monohydrate, i.v. Normal
blood glucose levels for rabbits varied between 100 mg/dL
and 150 mg/dL. Rabbits with blood glucose over
250 mg/dL were considered diabetic.14 There were no
signiﬁcant changes in the weights of the nondiabetic and
diabetic rabbits (Supplementary Table I, online only).
Surgical models. In each surgical group on day 10,
one ear served as an experimental ear and other as
a sham ear (Supplementary Fig 1, A, online only). In one
group, ischemia was created in the experimental ear by
ligating the central and the rostral artery leaving the caudal
artery and all the veins intact. In the second surgical group,
central and rostral arteries were ligated along with centraland rostral nerve resection creating the neuroischemia. In
the sham ears, arteries and nerves were dissected out but
not ligated or resected. Following surgery, in both ears,
four full-thickness circular wounds were created using a 6-
mm punch biopsy. The cartilage was kept intact since it
stents the wound open and minimizes tissue contracture to
less than 3%, allowing the wound to heal by re-eptheliali-
zation.15 On day 20, rabbits were euthanized and wound
tissue was harvested for analysis. This timepoint was chosen
based on the results of our previous study where we
observed that at least 50% of wounds heal in the nondia-
betic sham group.11 The Harvard Medical Area Standing
Committee on Animals approved all study procedures.
Wound area measurement. Postinjury, wound
healing was monitored for 10 days (from day 10 to 20).
Wounds were photographed using a Medical Hyper-
spectral Imaging camera (Hypermed Inc, Burlington,
Mass) and wound area was measured as change in pixels.
Tissue analysis. Punch biopsies and the wound
samples (1  1 cm, cut into four pieces) from each ear
were analyzed for gene (quantitative reverse transcriptase
polymerase chain reaction [qRT-PCR]) and protein
(immunohistochemistry-parafﬁn and -frozen and Western
blot) expression analysis.
Gene expression. Standard qRT-PCR was used to
quantitate and compare levels of speciﬁc RNA transcripts.
Primers (Supplementary Table VII, online only) were ob-
tained from Integrated DNA Technologies (Coralville,
Iowa). For quantitative analysis, target gene levels were
normalized to beta-actin levels. Gene expression in the
wound samples was measured as fold change over the
baseline gene expression.
Histology and immunohistochemistry. Tissue samples
were either formalin-ﬁxed parafﬁn-embedded or were optimal
cutting temperature-embedded and frozen. Standard his-
tology and histology and immunohistochemistry (IHC)
techniques were used. Antibody information is in
Supplementary Table III (online only). To conﬁrm speciﬁc
staining for each primary antibody, an isotype negative
control and a nonprimary antibody control was used. All
hematoxylin and eosin (H&E) staining and IHC readings
were performed in a blinded fashion and an arbitrary scale of
1-5 was used to grade them. H&E grading was performed on
the basis of the extent of leukocyte inﬁltration (distance cells
migrated from the wound margin) and intensity of leukocyte
inﬁltration (number of inﬁltrating cells). For immune cell
inﬁltration, neuropeptide and cytokine IHC, data are pre-
sented as fold change over the baseline inﬁltration. For
macrophage studies, the M1/M2 ratio is calculated from the
arbitrary raw scores. It is important to note that because of
very high numbers of positively stained total leukocytes
(H&E) and macrophages (both M1 and M2), it was not
possible to count the number of cells but to use an arbitrary
scale as explained above.
Western blot. Standard Western blot techniques were
used and speciﬁc antibody information is in Supplemental
Supplementary Table VIII (online only). Densitometry was
performed using Quantity One (Bio-Rad, Hercules, Calif)
Fig 1. Wound healing. Comparison between nondiabetic and
diabetic rabbit sham, ischemic, and neuroischemic wounds.
Wound healing was monitored over a 10-day period from days
10-20. Photographs were obtained on days 12, 15, and 20 using
a Medical Hyperspectral Imaging Camera. Using Adobe Photo-
shop, wound area was measured in pixels. Data are expressed as
percent change in wound area from days 12-20 (n ¼ 6-18,
mean 6 standard error of the mean; ***P < .001 and *P < .05).
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are presented in the form of densitometric analysis. Protein
expression in the wound samples was measured as fold
change over the baseline protein expression.
Data analysis and statistics. Data were compared
between nondiabetic and diabetic rabbits grouped into
their speciﬁc surgery. Representative images of Western
blot and immunohistochemistry are presented in the
supplemental data (Supplementary Figs 3-6, online only).
All data are expressed as the mean 6 standard error of the
mean and are analyzed using either one-way or two-way
ANOVA test. An unpaired t-test is performed and P <
.05 is considered statistically signiﬁcant. Statistical analysis
was done using Statview (SAS Inc, Cary, NC). In addition
to graphical representation of the data, numerical data are
presented in Supplementary Tables I-VI (online only). We
have also presented graphical data showing comparisons
between sham, ischemic, and neuroischemic wounds
within nondiabetic or diabetic rabbits in the Supplementary
document (Supplementary Figs 7-11, online only).
RESULTS
Compared to nondiabetic sham and ischemic
wounds, wound healing is impaired in diabetic sham
and ischemic wounds. Wound healing was impaired in
the diabetic sham and ischemic wounds at day 15 and day
20 when compared to nondiabetic wounds (Fig 1;
Supplementary Figs 1,B and 7, online only). Interestingly, no
differences between nondiabetic and diabetic neuroischemic
wounds were noted. However, among nondiabetic animals,
neuroischemic wounds showed the most impaired healing
when compared to the other nondiabetic wounds, compa-
rable to that observed in diabetic wounds. Across all diabetic
animal groups, minimal differences in the rate of wound
healing were noted. These results suggest that neuropathy
and ischemia have additive effects and that diabetes does not
further impair neuroischemic wound healing.
Preinjury diabetic rabbit skin shows signs of
inﬂammation (assessed by leukocyte inﬁltration), but
postinjury fails to mount a satisfactory inﬂammatory
response. In the present study, we evaluated the preinjury
(day 10) and postinjury (day 20 of experiment and 10 days
after surgery) leukocyte inﬁltration in the wounds, respec-
tively. In agreement with our previous ﬁndings, baseline
preinjury skin leukocyte inﬁltration (extent and intensity) was
higher in diabetic compared with nondiabetic rabbits (Fig 2,
A; Supplementary Fig 2, online only). Postinjury, the fold
increase over the baseline inﬁltration (extent and intensity)
was higher in nondiabetic sham, ischemic, and neuroischemic
wounds compared to diabetic wounds, clearly indicating an
impaired ability in the diabetic animals to mount an appro-
priate, focused leukocyte response after injury (Fig 2, B;
Supplementary Figs 2 and 8, online only).
Diabetic rabbits have increased M1/M2 macro-
phage ratio in their skin and wounds. Sincemacrophages
play an important role in both, tissue repair (M2 activation
pathway) and development of chronic wounds (M1 activa-
tion pathway), we calculated the M1/M2 ratio in the tissues
Fig 2. Leukocyte inﬁltration. Comparison between nondiabetic
and diabetic. Hematoxylin and eosin (H&E) stained cross-sections
were analyzed for leukocyte inﬁltration. An arbitrary scale of 1-5 was
used for grading entire cross-sections. Grading was performed on
the basis of extent of inﬁltration (distance the cellsmigrated from the
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CD18þ (M2) macrophages at baseline in the skin at day 10
and in the wounds at day 20 (Fig 3, A-C; Supplementary Fig
3, online only). Compared with nondiabetic, diabetic rabbits
had more M1 macrophages at baseline in the skin at day 10
and in the sham wounds at day 20 (Fig 3, A). M2 macro-
phages were less in diabetic rabbits both, at day 10 and in all
wounds at day 20 (Fig 3, B). This resulted in a higher M1/
M2 ratio in diabetic rabbits in all surgical conditions (Fig 3,C;
Supplementary Fig 9, online only). Moreover, there were
higher numbers ofM1macrophages in diabetic rabbit skin at
day 10 than there were M2 macrophages in nondiabetic
rabbit skin at day 10 probably resulting in an overall higher
number of leukocytes observed in diabetic rabbit skin at day
10.CD177þ neutrophils orCD3þT cells were not observed
in the skin of both nondiabetic and diabetic rabbits on day 10,
and there were no differences in their numbers between
nondiabetic and diabetic rabbits in any wounds at day 20.
However, in both nondiabetic and diabetic rabbits, the
neuroischemic wounds had the highest number of CD177þ
neutrophils (Fig 4, A) and CD3þ T cells (Fig 4, B). A higher
M1/M2 ratio indicated a proinﬂammatory, impaired heal-
ing environment in the diabetic rabbits, and presence of
CD177þ neutrophils suggests that the neuroischemic
wounds remained in a prolonged inﬂammatory phase of
wound healing.
Gene and protein expression of inﬂammatory
cytokines involved in wound healing follow the same
pattern as leukocyte inﬁltration. We evaluated the gene
and protein expression of the main cytokines that are
involved in wound healing. At baseline in the skin at day
10, diabetic rabbits showed a higher gene expression of
IL-8, CXCR1, and IL-6 with no differences in the protein
expression (Fig 5; Supplementary Figs 4 and 5, online
only). After creation of the wound, the reactive fold change
in gene expression over baseline of IL-6, IL-8, and CXCR1
was lower, or trended to be lower in all diabetic wounds
when compared to nondiabetic wounds (Fig 6, A;
Supplementary Fig 10, A, online only). The fold change
in protein expression over baseline was lowest for IL-6
followed by IL-8 and CXCR1 in diabetic wounds
when compared with nondiabetic wounds (Fig 6, B;
Supplementary Figs 4, 5, and 10, B, online only).
Gene and protein expression of neuropeptides,
their receptors, and enzymes that are involved in their
turnover are altered in diabetes. At baseline in the skin at
day 10, gene expression of DPPIV was higher, whereaswound margin) and the intensity of inﬁltration (number of inﬁl-
trating cells). Data are presented in the form of arbitrary scores. A,
Baseline comparison. Data are expressed as fold change in inﬁltra-
tion (extent and intensity) of diabetic rabbit skin compared with
nondiabetic rabbit skin (n ¼ 6-12, mean 6 standard error of the
mean; *P < .05). B, Postinjury comparison within sham, ischemic,
and neuroischemic wounds. Data are expressed as postinjury change
in inﬁltration (extent and intensity) over the baseline in nondiabetic
and diabetic rabbit wounds (n ¼ 5-6, mean6 standard error of the
mean; ***P < .001 and **P < .01).
Fig 3. Macrophage inﬁltration. Comparison between nondiabetic and diabetic optimal cutting temperature embedded
6-mm frozen tissue sections were stained for macrophage marker CD18 and costained for either M1 macrophage
activation marker HLA-DR or M2 macrophage activation marker CD206. Merged images (yellow) of HLA-DRþ (red)
and CD18þ (green) or CD206þ (red) and CD18þ (green) macrophages were obtained close to the wound margins
using standard ﬂuorescent microscopy. A, Representative images of M1þ macrophages. B, Representative images of
M2þ macrophages. Representative images are from nondiabetic and diabetic treatment groups at baseline and sham,
ischemic, and neuroischemic wounds (20). C, M1/M2 ratio. An arbitrary scale of 1-5 was used for grading cross-
section images. M1/M2 ratio was obtained based on arbitrary scores (n ¼ 3-4, mean 6 standard error of the mean;
***P < .001, **P < .01).
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abetic rabbits, while no other differences were observed in
the other factors. SP and NPY protein expression was lower
and DPPIV was higher in diabetic compared to nondia-
betic rabbits (Fig 5, A and B; Supplementary Figs 4 and
6, online only).
Compared with nondiabetic wounds, the fold change
in gene expression over baseline of SP was lower in thediabetic neuroischemic wounds, whereas the expression
of NPY was lower in the diabetic ischemic and neuroische-
mic wounds. DPPIV gene expression was lower in all types
of diabetic wounds. Interestingly, NK1R, NPY2R, and
NPY5R gene expression was not changed in any diabetic
wounds. NEP gene expression was reduced in the diabetic
neuroischemic wounds (Fig 7, A; Supplementary Fig 11,
A, online only).
Fig 4. Representative images of (A) CD177þ (neutrophil) and (B) CD3þ (T cell) inﬁltration. Formalin-ﬁxed
parafﬁn-embedded 6-mm cross-sections were stained with CD177 or CD3 primary antibody and analyzed for
neutrophils and T-cell inﬁltration, respectively. Representative images close to the wound margin are from nondiabetic
and diabetic treatment groups at baseline and sham, ischemic, and neuroischemic wounds (magniﬁcation, 40).
Arrows indicate staining for CD177þ or CD3þ cells.
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sion was not different between nondiabetic and diabetic
wounds except in neuroischemic wounds. NK1R protein
expression was increased in diabetic ischemic wounds.
NPY2R and NPY5R protein expression were increased in
diabetic neuroischemic wounds. (Fig 7, B; Supplementary
Figs 4, 6, and 11, B, online only).DISCUSSION
In this model, we have shown that the presence of
diabetes results in impaired wound healing in both sham
and ischemic wounds. Additionally, ischemia alone reduces
wound healing in nondiabetic animals with minimal reduc-
tion in diabetic rabbits. The presence of neuroischemia
results in the greatest impairment of healing in all animals
and is so severe that additional presence of diabetes does
not further impair wound healing. This may be partially
explained by the fact that two of the most relevant long-
term diabetes complications are tissue ischemia and
neuropathy. Diabetic animals have chronic cutaneous
inﬂammation, which can be detected prior to injury.
However, they fail to mount an adequate postinjury focal
inﬂammatory response indicated by failure to switch from
M1 to M2 macrophage phenotype and reduced cytokineexpression, both of which are required to achieve wound
healing.
In the present study, we used a clinically relevant
model that can serve to understand the pathophysiology
underlying diabetic wound healing impairment and can
be used for testing future therapeutics. Although Chien
et al have used the neuroischemic model to study tissue
phosphate contents, our study is the ﬁrst to compare the
differences in wound healing between the ischemic and
neuroischemic models.13 Moreover, our study is the ﬁrst
to analyze and compare in depth the expression of neuro-
immune markers in these models.
Diabetes is known to be associated with a systemic
proinﬂammatory state. Our recent clinical work shows
that diabetic patients have increased skin leukocyte inﬁl-
tration.6 Similar to the clinical ﬁndings, in the present
study, we observed an increased leukocyte inﬁltration in
the diabetic rabbit skin. Most likely, this increase was
due to the increased M1 macrophage inﬁltration that is
associated with chronic inﬂammation. Although pre-
injury chronic inﬂammation is deleterious for wound
healing, postinjury inﬂammation, mainly achieved by
adequate leukocyte inﬁltration and cytokine release, is
needed for complete wound healing. In almost all wound
types, the extent and intensity of acute inﬁltration was
Fig 5. Cytokine, neuropeptide, and their receptor expression. Comparison at baseline in the expression of interleukin
(IL)-8, C-X-C chemokine receptor 1 (CXCR1), IL-6, substance P (SP), neurokinin 1 receptor (NK1R), neprilysin
(NEP), neuropeptide Y (NPY), NPY receptor 2 (NPY2R), NPY receptor 5 (NPY5R), and dipeptidyl peptidase IV
(DPPIV) between nondiabetic and diabetic rabbits. A, Gene expression. Using standard quantitative real-time poly-
merase chain reaction (qRT-PCR) and 2DDCt analysis method, gene expression was analyzed. Data are expressed as
fold change over nondiabetic expression (n ¼ 12-15, mean 6 standard error of the mean; ***P < .001, **P < .01,
*P < .05). B, Protein expression. Using standard Western blot and immunohistochemistry methods, protein expression
was analyzed. For Western blot quantiﬁcation, densitometry was used. For immunohistochemistry quantiﬁcation, an
arbitrary scale of 1-5 was used for grading entire cross-sections. Data are expressed as fold change over nondiabetic
expression (n ¼ 6-12, mean 6 standard error of the mean; ***P < .001, **P < .01, *P < .05).
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Neuroischemic wounds that heal the slowest had the
highest baseline macrophage inﬁltration compared with
other wounds. These results suggest that, to achieve
successful wound healing, there is a critical threshold for
an increase in focused acute inﬁltration in response to
injury. Moreover, diabetes is associated with leukocyte dys-
regulation with irregular and/or insufﬁcient immune cell
activation and cytokine and growth factor secretion.
Therefore, in diabetic wounds, even though there may be
a comparable number of inﬁltrating leukocytes, they may
not reﬂect an adequate response to injury. Further analysis
of types of cells inﬁltrating the skin and wounds suggests
that, preinjury, diabetic rabbit skin has a higher number
of M1 while lower number of M2 macrophages. Although
there was no difference in the number of M1 macrophages
between nondiabetic and diabetic (ischemic and neuroi-
schemic) wounds, there was a lower number of M2 macro-
phages in all of the diabetic wounds leading to an overall
higher M1/M2 ratio in the diabetic wounds suggesting
a chronic wound environment. On day 20, almost all of
the inﬁltrating cells found in sham and ischemic wounds
were macrophages with a few CD177þ neutrophils and
CD3þ T cells. Only the neuroischemic wounds had high
numbers of CD177þ neutrophils and CD3þ T cells.Presence of neutrophils beyond the initial inﬂammatory
stage is a hallmark of chronic wounds.
Similar to our prior study, we found an upregulation of
IL-8, CXCR1, and IL-6 gene expression in diabetic rabbits
at baseline, suggesting a chronic proinﬂammatory effect of
diabetes.
Postinjury, the fold change from baseline gene and
protein expression of IL-8, CXCR1, and IL-6 was blunted
in all diabetic wounds compared to nondiabetic wounds
indicating that the diabetes-related chronic upregulation
of cytokine expression at baseline may hamper the much-
needed focused upregulation postinjury.
Neuroischemia may not have had any additional effect
on wound healing in the diabetic wounds because of the
already reduced baseline expression of neuropeptides SP
and NPY. Similar to other studies,16,17 the gene expres-
sion of the NEP, the enzyme that breaks down SP was
higher in diabetic animals, although it did not reach
statistical signiﬁcance. This might further reduce the
levels of SP and therefore negatively affect wound
healing. Similar to previous studies,18,19 the present study
showed decreased NK1R gene expression, the receptor
for SP. Current information regarding the expression of
NPY receptors in diabetes is inconsistent.19,20 In the
present study, at baseline, there was no difference in the
Fig 6. Cytokines and their receptors. Postinjury comparison in the expression of interleukin (IL)-8, C-X-C chemokine
receptor 1 (CXCR1), and IL-6 between nondiabetic and diabetic rabbits within sham, ischemic, and neuroischemic
wounds. A, Gene expression. Using standard quantitative real-time polymerase chain reaction (qRT-PCR) and 2DDCt
analysis method, gene expression was analyzed. Data are expressed as change of expression over the baseline in
nondiabetic and diabetic rabbit wounds (n ¼ 5-6, mean 6 standard error of the mean; **P < .01, *P < .05). B,
Protein expression. Using standard Western blot and immunohistochemistry methods, protein expression was analyzed.
For Western blot quantiﬁcation, densitometry was used. For immunohistochemistry quantiﬁcation, an arbitrary scale of
1-5 was used for grading entire cross-sections. Data are expressed as change of expression over the baseline in
nondiabetic and diabetic rabbit wounds (n ¼ 4-6, mean 6 standard error of the mean; **P < .01, *P < .05).
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 3 Pradhan Nabzdyk et al 773gene expression of NPY2R and NPY5R between nondia-
betic and diabetic rabbits. We did ﬁnd that preinjury, dia-
betes upregulated both gene and protein expression of
DPPIV.
Postinjury, there was a decrease from baseline in gene
expression of SP and NPY in all wounds. These results
suggest that injury itself, irrespective of diabetic status can
lead to downregulation of neuropeptide gene expression.
The decrease in SP gene expression was signiﬁcant between
nondiabetic and diabetic rabbits only in the neuroischemic
wounds, whereas the decrease in NPY was signiﬁcantbetween nondiabetic and diabetic rabbits in almost all
wound types. NK1R, NPY2R, and NPY5R gene expression
were not different between nondiabetic and diabetic
rabbits in any wounds. Gene expression of NEP was
increased over baseline in all wound types with no differ-
ences between nondiabetic and diabetic wounds except
in the neuroischemic wounds, where NEP expression is
decreased in diabetic wounds compared to nondiabetic
wounds, maybe to counteract the loss of SP. The relative
gene expression of DPPIV in sham and ischemic wounds
was lower in diabetic compared with nondiabetic wounds
Fig 7. Neuropeptides, their receptors, and related enzymes. Postinjury comparison in the expression of substance
P (SP), neurokinin 1 receptor (NK1R), neprilysin (NEP), neuropeptide Y (NPY), NPY receptor 2 (NPY2R), NPY
receptor 5 (NPY5R), and dipeptidyl peptidase IV (DPPIV) between nondiabetic and diabetic rabbits within sham,
ischemic, and neuroischemic wounds. A, Gene expression. Using standard quantitative real-time polymerase chain
reaction (qRT-PCR) and 2DDCt analysis method, gene expression was analyzed. Data are expressed as change of
expression over the baseline in nondiabetic and diabetic rabbit wounds (n ¼ 5-6, mean 6 standard error of the mean;
*P < .05). B, Protein expression. Using standard Western blot and immunohistochemistry methods, protein expression
was analyzed. For Western blot quantiﬁcation, densitometry was used. For immunohistochemistry quantiﬁcation, an
arbitrary scale of 1-5 was used for grading entire cross-sections. Data are expressed as change of expression over the
baseline in nondiabetic and diabetic rabbit wounds (n ¼ 4-6, mean 6 standard error of the mean; *P < .05).
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local wound expression of DPPIV can reduce the forma-
tion of the proangiogenic form of NPY and, thus, affect
wound healing. These data once again suggest that dia-
betes and neuroischemia can seriously affect angiogenesis
through the dysregulation of the NPY pathway in these
rabbits. This is an important ﬁnding because DPPIV is
known to break down incretins and, hence, DPPIV inhib-
itors are clinically used for glycemic control.
The goal of this present study was to use a wound
healing model that most closely resembles the human
pathophysiology to understand the role of cytokines and
neuropeptides in wound healing. Although the rabbit vascular
ischemia model is commonly used, there are few animalmodels of diabetic peripheral neuropathy, most of which are
rodents.21-23 The neuropathy/denervation model that we
have used, although not perfect, has been used to study the
effect of sensory denervation on hypertrophic scarring in the
absence of diabetes and vascular ischemia.24 Because of the
bidirectional connection between nerves and inﬂammatory
cells, in amodel of “denervation only,”we could expect partial
wound healing impairment most likely through dysregulation
of inﬂammation and deﬁciency of neuropeptides. We
acknowledge that at this time, more work needs to be done
to fully decipher the mechanisms underlying the wound
impairment in our model. Using in vitro models, our group
is also investigating the effect of neuropeptides on the indi-
vidual cellular components that are involved in wound
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 3 Pradhan Nabzdyk et al 775healing. We also acknowledge that the study has other limita-
tions. Our model is a type I diabetes model and although
commonly used for wound-healing studies, this may not
model precisely the complexities of type II diabetes. There-
fore, it will be interesting to use a high-fat-diet rabbit model
of diabetes and perform similar investigations. In the present
study, we used a 10-day time point postsurgery to evaluate
healing.However, it could be possible that healing is impaired
to the extent that it is delayed at that time point but not abro-
gated. Currently, our group is conducting studies where time
to wound closure is being evaluated along with an early post-
surgery euthanasia time point to investigate differences in
inﬂammation. Also, this model does not allow for investiga-
tion of the effect of pressure on wound healing. Pressure
points associated with deformities in insensate feet are
a common problem in diabetes that eludes a perfect animal
model at this time. Other limitations include discrepancy in
the gene and protein expression. Thus, for some genes that
were affected, we did not see a corresponding change in their
respective protein expression. This could be explained by the
fact that some of these genes, especially the neuropeptides and
the cytokines, undergo post-transcriptional and -translational
modiﬁcations. Moreover, there could be a delay in translation
of the gene expression changes to manifest in the protein
expression changes. Another limitation is the lack of speciﬁc
antibodies in such rabbits including PGP 9.5, and hence, we
could not monitor this critical neuronal marker. It should
also be emphasized that most antibodies that achieved
successful staining were speciﬁc for humans and required
time-consuming optimization.
In conclusion, this study suggests that neuroischemia
and diabetes have the greatest impact on the wound
healing outcome. Although there were no differences in
wound healing between nondiabetic and diabetic neuroi-
schemic wounds, there are clear differences at the molec-
ular level. This model can be very helpful in investigating
the pathophysiology of diabetic neuroischemic wound
healing and for testing new therapeutics for the treatment
of diabetic neuroischemic wounds.
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Supplementary Fig 1 (online only). Experimental setup and representative images of wounds. A, This schematic
depicts the protocol timeline, treatment and surgical groups, and an illustration of the rabbit ears indicating ischemic/
neuroischemic and sham ear. In the ischemic/neuroischemic ear, solid lines depict the incision site where the central
and the rostral arteries are ligated along with the central and rostral nerves. Dashed lines in the sham ear depict incision
site where the central and rostral artery and nerve are dissected but left intact. B, Wound healing was monitored over
a 10-day period from days 10-20. Photographs were obtained on days 12, 15, and 20 using a medical hyperspectral
imaging camera. Representative images are from nondiabetic and diabetic treatment groups of sham, ischemic, and
neuroischemic wounds obtained on day 20.
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Supplementary Fig 2 (online only). Representative hematoxylin and eosin (H&E) images of the wounds indicating
leukocyte inﬁltration. Formalin-ﬁxed parafﬁn-embedded H&E-stained 6-mm cross-sections were analyzed for leukocyte
inﬁltration. Representative images close to the wound margin are from nondiabetic and diabetic treatment groups and
at baseline and sham, ischemic, and neuroischemic wounds (magniﬁcation, 10 and 40). Arrows indicate staining for
immune cells.
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Supplementary Fig 3 (online only). Representative images of (A) M1þ and (B) M2þ macrophage inﬁltration.
Optimal cutting temperature embedded 6-mm tissue sections were stained for macrophage marker CD18 and costained
for M1 macrophage activation marker HLA-DR or M2 macrophage activation marker CD206. Representative images
close to the wound margin are from nondiabetic and diabetic treatment groups at baseline, and sham, ischemic, and
neuroischemic wounds (magniﬁcation, 5). Merged images (yellow/orange) of HLA-DRþ (red) and CD18þ (green)
M1 macrophages and merged images (yellow/orange) of CD206þ (red) and CD18þ (green) M2 macrophages were
obtained using standard ﬂuorescent microscopy.
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Supplementary Fig 4 (online only). Representative image of Western blot analysis. Representative Western blot
of C-X-C chemokine receptor 1 (CXCR1), neurokinin 1 receptor (NK1R), neuropeptide Y receptor 2 (NPY2R),
NPY receptor 5 (NPY5R), neprilysin (NEP), and dipeptidyl peptidase IV (DPPIV). Beta actin was used as a loading
control. Blots are from nondiabetic and diabetic treatment groups at baseline (B), and sham (S), ischemic (I), and
neuroischemic (NI) wounds.
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Supplementary Fig 5 (online only). Representative immunohistochemistry images of (A) interleukin (IL)-8 and (B)
IL-6. Optimal cutting temperature embedded 6-mm frozen cross-sections were ﬁxed with acetone and stained with
IL-8 primary antibody. Formalin-ﬁxed parafﬁn-embedded 6-mm cross-sections were stained with IL-6 primary anti-
body. Representative images close to the wound margin are from nondiabetic and diabetic treatment groups at baseline
and sham, ischemic, and neuroischemic wounds (magniﬁcation, 40). Arrows indicate staining for IL-8 or IL-6.
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Supplementary Fig 6 (online only). Representative immunohistochemistry images of (A) substance P (SP) and (B)
neuropeptide Y (NPY). Parafﬁn-embedded 6-mm cross-sections were stained with SP or NPY primary antibody.
Representative images close to the wound margin are from nondiabetic and diabetic treatment groups.
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Supplementary Fig 7 (online only). Wound healing. Compar-
ison between wound types (sham, ischemic, and neuroischemic)
within nondiabetic and diabetic treatment groups. Data are
expressed as percent change in wound area pixels of nondiabetic
and diabetic rabbits from days 2 to 10 (n ¼ 6-12; ***P < .001).
Supplementary Fig 8 (online only). Leukocyte inﬁltration.
Comparison between wound types (sham, ischemic, and neuro-
ischemic) within nondiabetic and diabetic treatment groups.
Hematoxylin and eosin (H&E) stained cross-sections were analyzed
for leukocyte inﬁltration. An arbitrary scale of 1-5 was used for
grading entire cross-sections. Gradingwas performed on the basis of
extent of inﬁltration (distance the cells migrated from the wound
margin) and intensity of inﬁltration (number of inﬁltrating cells).
Data are presented in the form of arbitrary scores (n¼ 5-6, mean6
standard error of the mean; ***P < .001 and **P < .01).
Supplementary Fig 9 (online only). Macrophage inﬁltration
(M1/M2 ratio). Comparison between wound types (sham,
ischemic, and neuroischemic) within nondiabetic and diabetic
treatment groups. Tissues were stained for M1-speciﬁc and M2-
speciﬁc macrophages as described before. An arbitrary scale of 1-5
was used for grading cross-section images. M1/M2 ratio was
obtained based on arbitrary scores (n ¼ 3-4, mean 6 standard
error of the mean; ***P < .001, **P < .01).
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Supplementary Fig 10 (online only). Cytokines and their receptors. Postinjury comparison in the expression of
interleukin (IL)-8, C-X-C chemokine receptor 1 (CXCR1), and IL-6 between wound types (sham, ischemic, and
neuroischemic) within nondiabetic and diabetic treatment groups. A, Gene expression. Using standard quantitative
real-time polymerase chain reaction (qRT-PCR) and 2DDCt analysis method, gene expression was analyzed. Data are
expressed as change of expression over the baseline in nondiabetic and diabetic rabbit wounds (n ¼ 5-6; ***P < .001,
**P < .01, P < .05). B, Protein expression. Using standard Western blot and immunohistochemistry methods, protein
expression was analyzed. For Western blot quantiﬁcation, densitometry was used. For immunohistochemistry quan-
tiﬁcation, an arbitrary scale of 1-5 was used for grading entire cross-sections. Data are expressed as change of expression
over the baseline in nondiabetic and diabetic rabbit wounds (n ¼ 4-6; ***P < .001, **P < .01, P < .05).
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Supplementary Fig 11 (online only). Neuropeptides and their receptors. Postinjury comparison in the expression of
substance P (SP), neurokinin 1 receptor (NK1R), neprilysin (NEP), neuropeptide Y (NPY), NPY receptor 2 (NPY2R),
NPY receptor 5 (NPY5R), and dipeptidyl peptidase IV (DPPIV) between wound types (sham, ischemic, and neuro-
ischemic) within nondiabetic and diabetic treatment groups. A, Gene expression. Using standard quantitative real-time
polymerase chain reaction (qRT-PCR) and 2DDCt analysis method, gene expression was analyzed. Data are expressed
as change of expression over the baseline in nondiabetic and diabetic rabbit wounds (n ¼ 5-6; ***P < .001, **P < .01,
P < .05). B, Protein expression. Using standard Western blot and immunohistochemistry methods, protein expression
was analyzed. For Western blot quantiﬁcation, densitometry was used. For immunohistochemistry quantiﬁcation, an
arbitrary scale of 1-5 was used for grading entire cross-sections. Data are expressed as change of expression over the
baseline in nondiabetic and diabetic rabbit wounds (n ¼ 4-6; ***P < .001, **P < .01, P < .05).
Supplementary Table I (online only). Weight and blood glucose data
Days
Nondiabetic (mean 6 SEM, n ¼ 15-18) Diabetic (mean 6 SEM, n ¼ 15-17)
Weight, kg Blood glucose, mg/dL Weight, kg Blood glucose, mg/dL
Comparisons made between nondiabetic and diabetic (aP < .001)
Day 0 3.115 6 0.057 176.595 6 11.625 3.253 6 0.068 176.595 6 11.625
Day 10 3.3 6 0.048 175.800 6 7.900 3.082 6 0.079 394.000 6 18.794a
Day 20 3.24 6 0.054 162.684 6 5.728 3.118 6 0.074 383.412 6 19.491a
SEM, Standard error of the mean.
Weight (kg) and fasting blood glucose (mg/dL) were obtained before alloxan administration (day 0), on day of surgery (day 10), and on day of euthanasia
(day 20). Results with signiﬁcant changes are in bold in the diabetic group (n ¼ 6-18, mean 6 SEM; aP < .001).
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Supplementary Table II (online only). Wound healing numerical data
Days
Sham Ischemic Neuroischemic
Nondiabetic Diabetic Nondiabetic Diabetic Nondiabetic Diabetic
% of original wound size (mean 6
SEM, n ¼ 15-18) % of original wound size (mean 6 SEM, n ¼ 5-6)
Comparisons made between nondiabetic and diabetic (aP < .001, bP < .05)
Day 12 100 6 0.0 100 6 0.0 100 6 0.0 100 6 0.0 100 6 0.0 100 6 0.0
Day 15 86.67 6 2.04 104.67 6 3.04a 84.91 6 1.6 94.29 6 2.57b 90.54 6 2.14 94.8 6 3.2
Day 20 53 6 3.23 78.801 6 4a 76.5 6 3.4 89.00 6 4.45b 81.92 6 2.28 86 6 3.9
SEM, Standard error of the mean.
Data are presented as % of original wound size (mean 6 SEM). Comparisons are made between nondiabetic and diabetic groups. Results with signiﬁcant
changes are in bold in the diabetic group (n ¼ 6-18, mean 6 SEM; aP < .001 and bP < .05).
Supplementary Table III (online only). Leukocyte inﬁltration data
Inﬁltration
Baseline Sham Ischemic Neuroischemic







n ¼ 15-17) Fold change over nondiabetic/diabetic baseline (mean 6 SEM, n ¼ 5-6)
Comparisons made between nondiabetic and diabetic (aP < .001, bP < .01, cP < .05)
Extent 1.0 6 0.028 1.325 6 0.067c 2.92 6 0.20 1.8 6 0.15a 2.7 6 0.106 1.546 6 0.22a 4.06 6 0.21 2.26 6
0.32b
SEM, Standard error of the mean.
Data are presented as the score of extent and intensity of inﬁltration (mean 6 SEM). Comparisons are made between nondiabetic and diabetic groups. Results
with signiﬁcant changes are in bold in the diabetic group (n ¼ 5-6, mean 6 SEM; aP < .001, bP < .01, and cP < .05).
Supplementary Table IV (online only). M1/M2 macrophage ratio
M1/M2
ratio
Baseline Sham Ischemic Neuroischemic








n ¼ 6) Fold change over nondiabetic/diabetic baseline (mean 6 SEM, n ¼ 3-6)
Comparisons made between nondiabetic and diabetic (aP < .001, bP < .01)
0.338 6 0.021 1.142 6
0.084a
0.65360.054 1.405 6 0.048a 0.597 6 0.062 1.414 6
0.099a
0.637 6 0.091 1.611 6
0.196b
SEM, Standard error of the mean.
Comparisons are made between nondiabetic and diabetic groups. Results with signiﬁcant changes are in bold in the diabetic group (n ¼ 3-4, mean 6 SEM;
aP < .001, bP < .01).
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Supplementary Table V (online only). Gene expression numerical data
Genes
Baseline Sham Ischemic Neuroischemic






n ¼ 15-17) Fold change over nondiabetic/diabetic baseline (mean 6 SEM, n ¼ 5-6)
Comparisons made between nondiabetic and diabetic (aP < .001, bP < .01, cP < .05)
IL-8 2.78 6 0.91 12.27 6 2.74b 3.36 6 1.49 0.78 6 0.38 6.33 6 2.7 0.996 6 0.25c 1.9 6 0.49 0.35 6 0.15c
CXCR1 4.46 6 1.65 54.45 6 9.85a 6.85 6 2.74 0.53 6 0.13c 18.24 6 5.3 1.03 6 0.18b 7.6 6 3.2 0.39 6 0.20c
IL-6 2.6 6 0.75 7.12 6 1.09c 1.044 6 0.248 0.269 6 0.08b 5.25 6 2.3 1.41 6 0.28b 2.76 6 1.1 0.16 6 0.02c
SP 2.88 6 1.06 2.78 6 1.39 0.38 6 0.0.054 0.23 6 0.11 0.42 6 0.09 0.26 6 0.03 0.63 6 0.18 0.24 6 0.09c
NK1R 0.75 6 0.158 0.39 6 0.06c 1.6 6 0.63 3.57 6 1.722 7.17 6 5.0 8.2 6 4.73 0.1 6 0.04 0.047 6 0.014
NEP 1.98 6 0.44 2.89 6 1.13 4.38 6 1.2 2.99 6 0.96 2.5 6 1.09 1.36 6 0.356 7.99 6 4.5 0.96 6 0.25c
NPY 2.22 6 0.82 3.13 6 0.97 1.425 6 0.66 0.47 6 0.152 0.64 6 0.25 0.12 6 0.026c 0.67 6 0.22 0.13 6 0.04c
NPY2R 4.49 6 1.83 13.104 6 4.23 2 6 0.83 0.36 6 0.28 4.037 6 2.79 0.46 6 0.078 2.26 6 2.05 0.11 6 0.03
NPY5R 5.25 6 2.1 14.85 6 4 0.66 6 0.22 0.17 6 0.006 1.13 6 0.363 0.3 6 0.067 1.77 6 1.56 0.11 6 0.04
DPPIV 2.3 6 0.96 6.14 6 1.5c 1.04 6 0.17 0.51 6 0.085c 1.51 6 0.198 0.97 6 0.17c 0.58 6 0.07 0.6 6 0.073
CXCR1, C-X-C chemokine receptor 1; DPPIV, dipeptidyl peptidase IV; IL-6/-8, interleukin-6/-8; NEP, neprilysin; NK1R, neurokinin 1 receptor; NPY,
neuropeptide Y; NPY2R, NPY receptor 2; NPY5R, NPY receptor 5; SEM, standard error of the mean; SP, subastance P.
Data are presented as relative gene expression (mean 6 SEM). Comparisons are made between nondiabetic and diabetic groups. Results with signiﬁcant
changes are in bold in the diabetic group (n ¼ 6-15, mean 6 SEM; aP < .001, bP < .01, cP < .05).
Supplementary Table VI (online only). Protein expression numerical data
Proteins
Baseline Sham Ischemic Neuroischemic






n ¼ 15-17) Fold change over nondiabetic/diabetic baseline (mean 6 SEM, n ¼ 5-6)
Comparisons made between nondiabetic and diabetic (aP < .001, bP < .05)
IL-8 1.0 6 0 1.103 6 0.04 1.39 6 0.12 1.27 6 0.07 1.49 6 0.15 1.081 6 0.13b 1.037 6 0.28 0.9 6 0.04
CXCR1 1.0 6 0 0.99 6 0.08 1.19 6 0.15 1 6 0.07 1.6 6 0.21 1.215 6 0.15 1.74 6 0.10 1.45 6 0.19
IL-6 1 6 0.084 1.13 6 0.07 1.53 6 0.11 1.036 6 0.07b 1.24 6 0.12 0.825 6 0.05b 1.96 6 0.16 1.21 6 0.11b
SP 1 6 0.034 0.609 6 0.04a 0.94 6 0.05 1.22 6 0.09 0.84 6 0.13 1.26 6 0.10 1.36 6 0.17 0.92 6 0.08b
NK1R 1.0 6 0 1.05 6 0.04 0.96 6 0.14 1.082 6 0.11 1.2 6 0.07 1.73 6 0.12b 1.15 6 0.122 0.88 6 0.08
NEP 1.0 6 0 1.16 6 0.23 1.146 6 0.13 1.22 6 0.13 2.21 6 0.74 1.55 6 0.27 1.6 6 0.18 1.58 6 0.13
NPY 1 6 0.104 0.6 6 0.06a 1.231 6 0.11 1.42 6 0.09 0.86 6 0.14 1.35 6 0.17 1 6 0.5 1.55 6 0.22
NPY2R 1.0 6 0 1.01 6 0.16 1.097 6 0.25 1.25 6 0.17 1.84 6 0.54 1.406 6 0.18 1.04 6 0.12 1.63 6 0.06b
NPY5R 1.0 6 0 0.98 6 0.12 0.99 6 0.15 1.18 6 0.18 1.23 6 0.23 1.56 6 0.04 1.33 6 0.16 1.58 6 0.12
DPPIV 1.0 6 0 1.68 6 0.34b 0.9 6 0.09 0.855 6 0.69 1.076 6 0.21 0.71 6 0.15 0.91 6 0.15 0.76 6 0.02
CXCR1, C-X-C chemokine receptor 1; DPPIV, dipeptidyl peptidase IV; IL-6/-8, interleukin-6/-8; NEP, neprilysin; NK1R, neurokinin 1 receptor; NPY,
neuropeptide Y; NPY2R, NPY receptor 2; NPY5R, NPY receptor 5; SEM, standard error of the mean; SP, subastance P.
Data are presented as relative protein expression (mean 6 SEM). Comparisons are made between nondiabetic and diabetic groups. Results with signiﬁcant
changes are in bold in the diabetic group (n ¼ 4-6, mean 6 SEM; aP < .001, bP < .05).
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Supplementary Table VII (online only). List of PCR primers
Gene qRT-PCR primer sequences
IL-8 F: CTC TGC TGG CTG CCC TAC
R: CTG ACA CGT CTC CTG GAT CA
CXCR1 F: GGC GCT GTC TCT GAT TTT GT
R: GGC TGG AAT TGT TTG GAG AA
IL-6 F: GTC AGC CTG ATG GAG AAC CT
R: GGA TGA AGT GGA TCG TGG TC
SP (preprotachykinin-A) F: TGT GTC TCA GGG CTG AAA TG
R: TAT GGA ACC ACA AAC CGT GA
NK1R F: TTG GCC CAC AAG AGA ATG AGG ACA
R: AGT ACC ACT CGT TGT GGA CAG CAT
NEP F: TGT GCA CAG TCC AGG CAA TTT CAG
R: TTC TGT AGA TCA CAA AAC CCG GCA
NPY (Pre-pro-NPY) F: CCA GCC CAG AGA CAC TGA TT
R: ACA TTG CAG GGT CTT CAA GC
NPY2R F: AAA TGA TGG TGT GTG TGG TGG TGG
R: AGT TGC TGT TCA TCC AGC CGT AGA
NPY5R F: TAA CAG CCA ACC ACG GCT ACT TCT
R: TCC TGC AGT TCC ACA AGA CTG TGA
DPPIV (SABiosciences Qiagen, Valencia, Calif Cat # PPH00035A)
Beta-actin F: TGT ATG AAG GCT TTT GCT CTC C
R: CTG GTC TCA AGT CAG TGT ACA GGT
CXCR1, C-X-C chemokine receptor 1; DPPIV, dipeptidyl peptidase IV; IL-6/-8, interleukin-6/-8; NEP, neprilysin; NK1R, neurokinin 1 receptor; NPY,
neuropeptide Y; NPY2R, NPY receptor 2; NPY5R, NPY receptor 5; qRT-PCR, quantitative real-time polymerase chain reaction; SP, subastance P.
Supplementary Table VIII (online only). List of antibodies for Western blot and immunohistochemistry
Western blot reagents
Antibody Company Catalog number Dilution Secondary antibody Company Catalog number Dilution
CXCR1 R&D Systems MAB 330 1:100 Goat-anti mouse R&D Systems HAF007 1:500
NK1R SCBT SC 14115 1:100 Donkey-anti goat SCBT SC2020 1:500
NEP R&D Systems MAB 1182 1:100 Rabbit-anti mouse Sigma Aldrich A9044 1:500
NPY2R SCBT SC 14736 1:100 Donkey-anti goat SCBT SC2020 1:500
NPY5R SCBT SC 23843 1:100 Donkey-anti goat SCBT SC2020 1:500
DPPIV R&D Systems AF 1180 1:250 Donkey-anti goat SCBT SC2020 1:500
Immunohistochemistry reagents
Antibody Section type Company
Catalog
number Dil Secondary antibody Company Catalog number
IL-8 OCT-Fr Abcam AB 10769 1:10 Anti-goat R&D Systems CTS008
IL-6 FFPE R&D Systems MAB 2061 1:50 Anti-mouse Vector Labs PK6102
SP FFPE SCBT SC 21715 1:25 Anti-rat SCBT SC 2019
NPY FFPE Abcam AB 1583 1:1000 Anti-sheep (1:100) Millipore AP 184B
CD177 FFPE Lifespan Biosciences LS-B1953 1:15 Anti-mouse Vector Labs PK6102
CD3 FFPE BD Biosciences 550367 1:15 Anti-mouse Vector Labs PK6102
CD18 OCT-Fr AbD Serotec MCA1780 1:15 Goat anti-mouse (1:400) AbD Serotec STAR117D488GA
HLA-DR OCT-Fr Abcam ab49388 1:100 Donkey anti-mouse (1:400) Jackson Labs 715-507-003
CD206 OCT-Fr AbD Serotec MCA2155 1:100 Donkey anti-mouse (1:400) Jackson Labs 715-507-003
CD, Cluster of differentiation; CXCR1, C-X-C chemokine receptor 1; DPPIV, dipeptidyl peptidase IV; FFPE, formalin-ﬁxed parafﬁn-embedded; HLA-DR,
human leukocyte antigen-DR; IL-6/-8, interleukin-6/-8; NEP, neprilysin; NK1R, neurokinin 1 receptor; NPY2R, neuropeptide Y receptor 2; NPY5R, NPY
receptor 5; OCT-Fr, optimal cutting temperature frozen; SP, substance P.
CD18-CD206 and CD18-HLA-DR were costained using standardized protocol. DAPI (40,6-diamidino-2-phenylindole, dihydrochloride), Life Technologies
Corporation Cat# D1306 was used (1:1000) for staining nuclei.
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